One-Year Survival and Postoperative Complications in Older Patients with Intertrochanteric Fractures: Association with Polypharmacy-A Multicenter Retrospective Cohort Study.

IF 3.4 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Drugs & Aging Pub Date : 2025-05-01 Epub Date: 2025-04-29 DOI:10.1007/s40266-025-01194-5
Yasuhiko Takegami, Yusuke Osawa, Hiroto Funahashi, Takamune Asamoto, Hiroaki Ido, Keiji Otaka, Shinya Tanaka, Hiroshi Asai, Hiroyuki Yokoi, Shiro Imagama
{"title":"One-Year Survival and Postoperative Complications in Older Patients with Intertrochanteric Fractures: Association with Polypharmacy-A Multicenter Retrospective Cohort Study.","authors":"Yasuhiko Takegami, Yusuke Osawa, Hiroto Funahashi, Takamune Asamoto, Hiroaki Ido, Keiji Otaka, Shinya Tanaka, Hiroshi Asai, Hiroyuki Yokoi, Shiro Imagama","doi":"10.1007/s40266-025-01194-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Polypharmacy is common in older patients and associated with adverse outcomes. However, the association with outcomes in patients with intertrochanteric fractures remains unclear. This study aimed to investigate associations between polypharmacy and 1-year survival (primary outcome) and postoperative complications (secondary outcome), in older patients undergoing surgical treatment for intertrochanteric fractures.</p><p><strong>Patients and methods: </strong>This multicenter retrospective study initially identified 1864 patients who underwent surgical treatment for intertrochanteric fractures between 2016 and 2020. We excluded those aged < 65 years, with polytrauma, or with Charlson Comorbidity Index (CCI) > 3 or insufficient data. Patients were classified into polypharmacy (≥ 5 medications) and non-polypharmacy (< 5 medications) groups. We performed two analyses: (1) complete case analysis using 1:1 propensity score matching (498 pairs) with variables including age, sex, body mass index (BMI), CCI, residence before admission, fracture type, American Society of Anesthesiologists (ASA) physical status (PS), and Parker Mobility Score, followed by Kaplan-Meier survival analysis with log-rank test and chi-squared test for complications and (2) multivariate Cox regression analysis using multiple imputation (CART method, five imputed datasets) of the eligible cohort (N = 1608), adjusting for the same variables.</p><p><strong>Results: </strong>In the matched cohort, the 1-year survival rate was significantly lower in the polypharmacy group (91.3%; 95% CI 87.7-93.8) compared with the non-polypharmacy group (94.0%; 95% CI 90.9-96.1; P = 0.027). Postoperative complications showed no significant differences between groups. Cox regression analysis revealed that advanced age, male sex, ASA-PS, and polypharmacy were associated with decreased survival, while higher Parker Mobility Score and normal and higher BMI showed improved survival.</p><p><strong>Conclusions: </strong>Polypharmacy was associated with lower postoperative survival in older patients with intertrochanteric fractures and few comorbidities. As a potentially modifiable factor, medication review through multidisciplinary collaboration might contribute to improved outcomes.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":"42 5","pages":"435-444"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-025-01194-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Polypharmacy is common in older patients and associated with adverse outcomes. However, the association with outcomes in patients with intertrochanteric fractures remains unclear. This study aimed to investigate associations between polypharmacy and 1-year survival (primary outcome) and postoperative complications (secondary outcome), in older patients undergoing surgical treatment for intertrochanteric fractures.

Patients and methods: This multicenter retrospective study initially identified 1864 patients who underwent surgical treatment for intertrochanteric fractures between 2016 and 2020. We excluded those aged < 65 years, with polytrauma, or with Charlson Comorbidity Index (CCI) > 3 or insufficient data. Patients were classified into polypharmacy (≥ 5 medications) and non-polypharmacy (< 5 medications) groups. We performed two analyses: (1) complete case analysis using 1:1 propensity score matching (498 pairs) with variables including age, sex, body mass index (BMI), CCI, residence before admission, fracture type, American Society of Anesthesiologists (ASA) physical status (PS), and Parker Mobility Score, followed by Kaplan-Meier survival analysis with log-rank test and chi-squared test for complications and (2) multivariate Cox regression analysis using multiple imputation (CART method, five imputed datasets) of the eligible cohort (N = 1608), adjusting for the same variables.

Results: In the matched cohort, the 1-year survival rate was significantly lower in the polypharmacy group (91.3%; 95% CI 87.7-93.8) compared with the non-polypharmacy group (94.0%; 95% CI 90.9-96.1; P = 0.027). Postoperative complications showed no significant differences between groups. Cox regression analysis revealed that advanced age, male sex, ASA-PS, and polypharmacy were associated with decreased survival, while higher Parker Mobility Score and normal and higher BMI showed improved survival.

Conclusions: Polypharmacy was associated with lower postoperative survival in older patients with intertrochanteric fractures and few comorbidities. As a potentially modifiable factor, medication review through multidisciplinary collaboration might contribute to improved outcomes.

老年粗隆间骨折患者的1年生存率和术后并发症:与多药相关的多中心回顾性队列研究
多重用药在老年患者中很常见,并与不良后果相关。然而,与转子间骨折患者预后的关系尚不清楚。本研究旨在探讨在接受粗隆间骨折手术治疗的老年患者中,多药治疗与1年生存率(主要结局)和术后并发症(次要结局)之间的关系。患者和方法:这项多中心回顾性研究最初确定了2016年至2020年期间接受手术治疗的1864例粗隆间骨折患者。我们排除了年龄< 65岁、多发外伤、Charlson合并症指数(CCI) bb103或资料不足的患者。患者分为多药组(≥5种药物)和非多药组(< 5种药物)。我们进行了两项分析:(1)以年龄、性别、体重指数(BMI)、CCI、入院前居住、骨折类型、美国麻醉医师协会(ASA)身体状况(PS)、Parker活动能力评分为变量,采用1:1倾向评分匹配(498对)完成病例分析,对并发症进行Kaplan-Meier生存分析,采用log-rank检验和卡方检验;(2)采用多重插值(CART)方法进行多变量Cox回归分析。(N = 1608),对相同的变量进行调整。结果:在匹配的队列中,多药组的1年生存率明显较低(91.3%;95% CI 87.7-93.8)与非多药组(94.0%;95% ci 90.9 ~ 96.1;P = 0.027)。术后并发症组间无明显差异。Cox回归分析显示,高龄、男性、ASA-PS和多药均与生存率降低相关,而较高的Parker活动能力评分、正常和较高的BMI均可提高生存率。结论:老年股骨粗隆间骨折患者多药治疗与较低的术后生存率和较少的合并症有关。作为一个潜在的可修改的因素,通过多学科合作的药物审查可能有助于改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drugs & Aging
Drugs & Aging 医学-老年医学
CiteScore
5.50
自引率
7.10%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信